The European Commission granted CSL Behring approval to market Privigen, an intravenous immune globulin, as a treatment for chronic inflammatory demyelinating polyneuropathy. Positive results from the Privigen Impact on Mobility and Autonomy trial were cited in the application.
EU approves CSL Behring's Privigen for CIDP
SmartBrief Job Listings for Health Care
|Chief Operating Officer||
Presence Health Partners
|Des Plaines, IL|
|Sr. Business Systems Analyst||
|Sr. Reimbursement Analyst||
Olympus America Inc.
|Leadership Recruiting Manager||
|Strategic Partner Relationship Executive||
Geisinger Health System